We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Feather Safety Razor

Download Mobile App

Moderna's Phase III COVID-19 Vaccine Trial Delayed

By HospiMedica International staff writers
Posted on 06 Jul 2020
Print article
Human trials of Moderna, Inc.’s (Cambridge, MA, USA) COVID-19 vaccine candidate that were expected to begin next week have been reportedly delayed.

Recent preliminary data from animal studies released by the US National Institutes of Allergy and Infectious Disease (NIAID) and Moderna had demonstrated that its COVID-19 vaccine candidate was unlikely to increase the risk of the disease becoming more severe and only a single dose could provide protection against the novel coronavirus. Moderna is currently conducting human trials of its COVID-19 vaccine candidate and had announced plans to initiate final-stage trials in July that would involve 30,000 volunteers. Investigators at the University of Illinois had said that Moderna’s trial would begin on July 9, while the National Institutes of Health (NIH) Director, Francis Collins had told lawmakers in Washington that the study would begin in July.

However, a report by STAT has said that Moderna is making changes to its trial plan, called a protocol, resulting in the expected start date of the Phase 3 study being postponed. According to investigators who spoke to STAT, protocol changes are common, although it was not clear how long the start would be delayed.

“My understanding was that they wanted to get the first vaccines given in July, and they say they’re still committed to do that,” an investigator told STAT. “As best I can tell, they’re close to being on target for that.”

Nevertheless, after the publication of the report by STAT, CEO Stéphane Bancel told CNBC that Moderna planned to go ahead with the trial in July while the company posted a statement on Twitter saying that it has “worked closely” with the National Institutes of Health, which is funding the Phase 3 study, “to align the final protocol in order to begin the trial on time.”

Related Links:
Moderna, Inc.

Print article


Surgical Techniques

view channel
Image: Robotic surgery has been found to improve patient recovery time (Photo courtesy of Pexels)

Robotic Surgery Found to Be Safer, Reduces Patient Time in Hospital

Unlike open surgery, where a surgeon works directly on a patient and involves large incisions in the skin and muscle, robot-assisted surgery allows surgeons to guide minimally invasive instruments remotely... Read more

Patient Care

view channel
Image: Future wearable health tech could measure gases released from skin (Photo courtesy of Pexels)

Wearable Health Tech Could Measure Gases Released From Skin to Monitor Metabolic Diseases

Most research on measuring human biomarkers, which are measures of a body’s health, rely on electrical signals to sense the chemicals excreted in sweat. But sensors that rely on perspiration often require... Read more

Health IT

view channel
Image: AI can reveal a patient`s heart health (Photo courtesy of Mayo Clinic)

AI Trained for Specific Vocal Biomarkers Could Accurately Predict Coronary Artery Disease

Earlier studies have examined the use of voice analysis for identifying voice markers associated with coronary artery disease (CAD) and heart failure. Other research groups have explored the use of similar... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.